0, 100, 200: How Trump's latest generic medicines tariffs could affect India
US President Donald Trump announced phased tariffs on imported generic medicines, starting with zero tariffs from August 1, 2026, for two years.
Tariffs will rise to 100% from August 2028 and 200% from August 2029, aiming to encourage manufacturing in the United States.
Indian drugmakers export approximately $9-10 billion worth of generic medicines to the US annually, accounting for nearly 40% of generic medicines used in the US.
India's pharmaceutical exports to the US stood at $10.5 billion in 2024-25, making medicines a top export category.
The tariff plan targets reshoring generic pharmaceutical production to America, potentially impacting India's role as the 'pharmacy of the world'.
Story angle
Center-left
Mostly straight facts, with a light progressive or opposition-friendly tilt.
About how the story is framed, not whether the facts are true.
Hindustan Times
Center-left
Mixed factuality
